As global transparency mandates continue expanding, disclosure shifts from a submission exercise to an enterprise governance priority. Biopharmas must balance increasing regulatory expectations while protecting commercially confidential information (CCI), intellectual property, and competitive positioning.

Join Veeva and Real Life Sciences (RLS) to discuss how integrated disclosure, redaction, and anonymization workflows support oversight, risk mitigation, and compliance. Learn how connectivity, automation, and structured governance models help protect competitive advantage while maintaining transparency.

• Shifting from reactive, late stage redaction to proactive governance
• Embedding anonymization and CCI controls directly into disclosure workflows
• Integrating Veeva Disclosures with RLS to strengthen monitoring and audit readiness
• Reducing manual review burden while improving consistency and defensibility
• Scaling compliance operations within increasingly complex regulatory environments

Sponsored by:

Speakers:

Matt DeFranco
Senior Director of Disclosures Strategy
Veeva Systems

Nirpal Virdee
Vice President and General Manager, Regulatory Solutions
Real Life Sciences